Wegovy in Canada: current uses and access

Wegovy at a glance

A prescription semaglutide product authorized for chronic weight management in patients who meet its criteria. The current monograph also includes a non-fatal heart-attack risk-reduction indication and a conditional authorization for defined adults with MASH and liver fibrosis.^[1]

Wegovy’s indication set must stay product-specific

Wegovy is not simply another name for Ozempic. The shared ingredient does not erase differences in indications, presentations and instructions. See the semaglutide ingredient guide for the full product family.

The current monograph is the controlling source for eligibility and use. A conditional authorization is still an authorization, but continued approval may depend on confirmatory evidence; it should not be described as identical to an authorization without conditions.^[1][2][3]

One brand can still involve different clinical questions

The relevant assessment depends on the treatment question. Weight-management care, cardiovascular risk reduction and MASH are not interchangeable reasons for prescribing. A clinician must connect the applicable monograph criteria with health history, current treatment and follow-up.

Read the conditional MASH authorization precisely

The current monograph identifies the MASH use as authorized with conditions. That is an authorization, but it carries a confirmatory-evidence condition and should not be described as equivalent to an authorization without conditions.

The cited DPD record, DIN 02528509, is one Marketed multi-dose pen presentation. Other Wegovy presentations have separate records, so verify the exact DIN before making a lifecycle, stock or coverage statement.

Ask the payer which authorized use and DIN its criteria address, then obtain the exact presentation’s pharmacy quote. The coverage workflow keeps those two decisions separate.^[1][2][3][4]